Background
Methods
Data sources and searches
Study selection
Data extraction and quality assessment
Data synthesis and analysis
Results
Characteristics of included prospective studies
Author, publication year | Cohort, country | Design, follow-up years | Population, cases/total no. of subjects | Age (years), female (%), and ethnicity | BMI (kg/m2), thyroid medicine users (%) | Outcomes | Covariates adjusted in models |
---|---|---|---|---|---|---|---|
M Thvilum, 2013 [32] | Official Danish health registers study, Denmark | Prospective cohort study, mean: 6 years | Danish national patient registry population, 1020/14,480 | Mean: 58, 84% of women, NR | NR, no | T2DM | Age and sex. |
N Gronich, 2015 [2] | NR, Israel | Prospective cohort study, 5–7 years | Statin non-users 3666/20,334 | 40–80, 62.11% of women, NR | Obesity (43.63%), mixed | DM | Age, sex, race, obesity, smoking, glucose, LDL, HDL, TG, history of hypertension, and drug use. |
N Gronich, 2015 [2] | NR, Israel | Prospective cohort study, 5–7 years | Statin users, 4410/39,263 | 40–80, 62.24% of women, NR | Obesity (44.3%), mixed | DM | Age, sex, race, obesity, smoking, glucose, LDL, HDL, TG, history of hypertension, and drug use. |
J-E Jun, 2016 [33] | NR, Korea | Prospective cohort study, 7 years | Population-based, 229/6235 | ≥ 18, 41.96% of women, NR | Mean (SD): 23.7 (2.56), no | T2DM | Age, sex, BMI, HbA1c, HDL, TG, LDL, smoking, lipid drug use, hypertension, BMI change. |
L Mehran, 2016 [34] | Tehran Thyroid Study, Iran | Prospective cohort study, median: 9.73 years | Population-based, NR/2316 | ≥ 20, NR, NR | Mean (SD): 25.3 (4.3), no | High-fasting blood glucose | Age, sex, smoking, BMI, and HOMA-IR. |
L Chaker, 2016 [35] | The Rotterdam Study, Netherlands | Prospective cohort study, mean: 7.9 years | Healthy population-based, 757/8107 | Mean: 64.6, 58% of women, NR | Mean (SD): 26.5 (4.05), mixed | DM | Sex, age, smoking, cohort, FSG levels, insulin, SBP, DBP, antihypertensive drugs, HDL cholesterol, and BMI. |
C-H Chang, 2017 [27] | NR, China | Prospective cohort study, median: 2.6 years | Population-based, 1551/68,846 | Mean: 41.2, 52.5% of women, NR | Obesity (3.2%), no | Dysglycemia, prediabetes, and T2DM | Sex, age, education level, smoking, drinking, and obesity. |
N M.Y. Journy, 2017 [36] | U.S. radiologic technologist cohort, USA | Prospective cohort study, median: 28 years | Women, 163/75,076 | 20-89, 100% of women, multiple | NR, mixed | T2DM deaths | Baseline year, age, race, BMI, family history of breast cancer, lifestyle, reproductive factors. |
T. Ittermann, 2017a [37] | Study of Health in Pomerania, Germany | Prospective cohort study, median: 5 years | Population-based, 116/2689 | 20–79, 51.2% of women, NR | Mean (SD): 27.2 (4.7), mixed | T2DM | Age and sex. |
T. Ittermann, 2017a [37] | INTER99, Denmark | Secondary analysis of RCT, 5 years | Population-based, 142/3815 | 30–60, 49.9% of women, NR | Mean (SD): 26.3 (4.6), NR | T2DM | Age and sex. |
T. I. de Vries, 2018 [38] | SMART study, Netherlands | Prospective cohort study, 2.9–8.3 years | With high cardiovascular risk, 289/5542 | Mean: 56, 35.24% of women, NR | Mean (SD): 26.72 (4), no | T2DM | Age, sex, current smoking, total and HDL cholesterol, and triglycerides |
R-H Chen, 2019 [39] | NR, China | Prospective cohort study, 10 years | Population-based, 5485/91,120 | ≥ 18, 77.4% of women, NR | Obesity (0.7%), NR | T2DM | Age, sex, and comorbidities. |
H-S Chen, 2007 [40] | NR, China | Prospective cohort study, 3–4.3 years | T2DM patients, CVD: 61, CVD deaths: 12, deaths: 31/556 | ≥ 30, 35.07% of women, NR | Mean (SD): 26.11 (9.8), mixed | CVD events, CVD deaths, and all-cause deaths | Age, sex, HbA1c, TC, HDL, BP, BMI, smoking, medication, urinary albumin, creatinine |
C Drechsler, 2014 [41] | NR, China | Prospective cohort study, 4 years | Diabetic hemodialysis patients, sudden death: 120 MI: 156, stroke: 70, CV events: 345, deaths: 441/ 934 | 18-80, 46.26% of women, NR | Mean (SD): 27.6 (4.98), NR | Sudden death, MI, stroke, combined CV events, all-cause death | Age, sex, atorvastatin, SBP, BMI, left ventricular hypertrophy, albumin, creatinine, N-terminal pro2B-type natriuretic peptide, ultrafiltration volume. |
J Geng, 2014 [42] | NR, China | Prospective cohort study, 2–3 years | T2DM patients, CHD: 32, new AF: 14, deaths: 10/694 | Mean: 56.1, 32.75% of women, NR | Mean (SD): 25.13 (3.63), NR | CHD events, new-AF, and all-cause deaths | Age, sex, hypertension, total cholesterol, LDL-cholesterol, smoking, SBP, DBP, and BMI. |
T I. de Vries, 2019 [26] | SMART study, Netherlands | Prospective cohort study, 3.3–9.6 years | T2DM patients, CVD: 191, deaths: 204/1265 | Mean 61, 26.64% of women, NR | Mean (SD): 29.22 (5), NR | CVD, all-cause deaths | Age, sex, smoking, history of vascular disease, eGFR, SBP, TC, and HDL-C. |
Thyroid function levels and risk of T2DM
Dose-response association between thyroid function levels and T2DM risk
Subgroup and sensitivity analyses
Subgroups | High TSH levels (> 2.21 mIU/L) | Low TSH levels (< 1.5 mIU/L) | ||||
---|---|---|---|---|---|---|
No. of studies | RR (95% CI) | P value | No. of studies | RR (95% CI) | P value | |
Age, yearsa | ||||||
< 60 | 9 | 1.104 (0.965; 1.263) | 0.182 | 5 | 1.113 (0.945; 1.309) | 0.299 |
≥ 60 | 4 | 1.376 (1.025; 1.847) | 4 | 0.897 (0.618; 1.302) | ||
Sex | ||||||
Women (≥ 50%) | 9 | 1.252 (1.058; 1.483) | 0.065 | 6 | 1.003 (0.752; 1.337) | 0.521 |
Women (< 50%) | 4 | 0.978 (0.799; 1.197) | 3 | 1.120 (0.938; 1.337) | ||
Study location | ||||||
Asia | 6 | 1.264 (0.997; 1.604) | 0.377 | 5 | 1.099 (0.852; 1.417) | 0.251 |
Europe & the USA | 6 | 1.113 (0.955; 1.298) | 3 | 0.851 (0.596; 1.215) | ||
BMI, kg/m2a | ||||||
Normal | 2 | 1.404 (1.072; 1.840) | 0.005 | 2 | 1.093 (0.780; 1.533) | 0.238 |
Overweight/obese | 5 | 1.009 (0.945; 1.077) | 2 | 0.784 (0.579; 1.062) | ||
Not Reported | 5 | 1.381 (1.074; 1.777) | 4 | 1.096 (0.785; 1.530) | ||
Follow-up years | ||||||
≤ 5 years | 4 | 1.004 (0.912; 1.105) | 0.024 | 2 | 1.141 (0.955; 1.363) | 0.251 |
> 5 years | 9 | 1.263 (1.060; 1.505) | 7 | 0.959 (0.757; 1.216) | ||
Thyroid medicine users | ||||||
No | 9 | 1.204 (1.002; 1.447) | 0.617 | 4 | 0.899 (0.773; 1.045) | 0.007 |
Mixed (yes & no) | 4 | 1.084 (0.900; 1.306) | 2 | 1.076 (0.828; 1.398) | ||
Not Reported | 2 | 1.057 (0.846; 1.321) | 3 | 1.236 (1.155; 1.322) | ||
Sample size | ||||||
≤ median | 6 | 1.234 (0.953; 1.599) | 0.587 | 3 | 0.844 (0.592; 1.202) | 0.071 |
> median | 6 | 1.138 (0.989; 1.309) | 5 | 1.190 (1.058; 1.340) | ||
Quality score | ||||||
6 stars | 4 | 1.127 (0.940; 1.350) | 0.240 | 3 | 1.156 (0.942; 1.419) | 0.405 |
7 stars | 5 | 1.075 (0.908; 1.272) | 2 | 1.050 (0.845; 1.304) | ||
8 stars | 3 | 1.502 (1.057; 2.134) | 3 | 0.806 (0.490; 1.326) | ||
Outcomes | ||||||
T2DM | 5 | 1.059 (0.944; 1.188) | 0.127 | 4 | 0.970 (0 .750; 1.256) | 0.722 |
T2DM & T1DM | 7 | 1.297 (1.048; 1.606) | 4 | 1.057 (0.7 11; 1 .574) |